Tourmaline Oil Corp. closed 7.6% below its 52-week high of C$70.83, which the company reached on February 21st.

Wedbush raised the firm’s price target on Tourmaline Bio (TRML) to $43 from $42 and keeps an Outperform rating on the shares. All key ...

H.C. Wainwright raised the firm’s price target on Tourmaline Bio (TRML) to $50 from $49 and keeps a Buy rating on the shares following the Q4 ...

Tourmaline Oil Corp. closed 6.2% below its 52-week high of C$70.83, which the company achieved on February 21st.

Tourmaline strategically pivoted from natural gas to liquids production amid pricing challenges. See why we believe TRMLF ...

The market expects Tourmaline Oil Corp. (TRMLF) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known ...

The retail merchandising company is leasing the top floor at Apex at Legacy, owned by Monarch Alternative Capital and ...

Analysts at Wedbush issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued on Thursday, March 6th. Wedbush analyst L. Chico expects that the company will post ...

Tourmaline Oil remains Canada’s largest natural gas producer and continues to reward investors through both regular and special dividends. In its most recent earnings, Tourmaline reported revenue of ...

Read Our Latest Stock Analysis on TRML Tourmaline Bio Trading Down 1.2 % Tourmaline Bio stock opened at $12.79 on Wednesday. Tourmaline Bio has a 1-year low of $11.87 and a 1-year high of $48.31 ...